AbbVie Inc.
ABOUT US
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas.
1 North Waukegan Road
North Chicago, IL 60064
(800) 240-1043
abbvie.com
PRIMARY CONTACTS
Shirley Garza-Gongora
Federal Account Executive
(210) 478-6074
shirley.garzagongora@abbvie.com
Ashley Polce
Federal Medical Outcomes Science Liaison
(314) 439-6040
ashley.polce@abbvie.com
PRODUCTS OR SERVICES
VENCLEXTA is a BCL-2 inhibitor indicated:
-
- For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
-
- In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
LUPRON DEPOT (leuprolide acetate for depot suspension):
-
- Is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostatic cancer.